StreetInsider.com News Articles

Form 4 Gain Therapeutics, Inc. For: Jul 15 Filed by: Nicaise Claude

Fri, 17 Jul 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260717/26782270.html

Form 4 Gain Therapeutics, Inc. For: Jul 15 Filed by: Nicaise Claude

Fri, 17 Jul 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260717/26782270.html

Form 4 Gain Therapeutics, Inc. For: Jul 15 Filed by: GOLDSTEIN DOV A MD

Fri, 17 Jul 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260717/26782275.html

Form 4 Gain Therapeutics, Inc. For: Jul 15 Filed by: GOLDSTEIN DOV A MD

Fri, 17 Jul 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260717/26782275.html

Form 4 Gain Therapeutics, Inc. For: Jul 15 Filed by: Islam Khalid

Fri, 17 Jul 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260717/26782267.html

Form 4 Gain Therapeutics, Inc. For: Jul 15 Filed by: Islam Khalid

Fri, 17 Jul 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260717/26782267.html

Form 4 Gain Therapeutics, Inc. For: Jul 15 Filed by: Riley Jeffrey Scott

Fri, 17 Jul 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260717/26782257.html

Form 4 Gain Therapeutics, Inc. For: Jul 15 Filed by: Riley Jeffrey Scott

Fri, 17 Jul 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260717/26782257.html

Form 4 Gain Therapeutics, Inc. For: Jul 15 Filed by: Melincoff Gwen A

Fri, 17 Jul 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260717/26782262.html

Form 4 Gain Therapeutics, Inc. For: Jul 15 Filed by: Melincoff Gwen A

Fri, 17 Jul 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260717/26782262.html

Form 4 Gain Therapeutics, Inc. For: Jul 15 Filed by: HASLER HANS PETER

Fri, 17 Jul 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260717/26782247.html

Form 4 Gain Therapeutics, Inc. For: Jul 15 Filed by: HASLER HANS PETER

Fri, 17 Jul 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260717/26782247.html

Form 8-K Gain Therapeutics, Inc. For: Jul 16

Thu, 16 Jul 2026 07:53:00 -0400

si-local-file:///var/storage/secattach/20260716/26776800.html

Form 8-K Gain Therapeutics, Inc. For: Jul 16

Thu, 16 Jul 2026 07:53:00 -0400

si-local-file:///var/storage/secattach/20260716/26776800.html

Gain Therapeutics updates rexaceract trial data, plans Phase 2 start

Thu, 16 Jul 2026 07:00:18 -0400

Gain Therapeutics, Inc. (Nasdaq: GANX) issued a shareholder letter outlining clinical progress for its lead Parkinson's disease drug candidate, rexaceract, and announced two executive promotions, according to a company statement.

All 16 participants in the ongoing Phase 1b open-label extension study remained enrolled at Day 150. Following a review on July 6, 2026, an independent Data Monitoring Committee recommended the study continue without modification. Longer-term outcomes are expected to read out in October 2026, with interim updates at 270 days anticipated over the summer.

Among participants with elevated baseline levels of glucosylsphingosine (GluSph) in cerebrospinal fluid, the compound produced an average 81%

Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update

Thu, 16 Jul 2026 07:00:00 -0400

BETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today provided the following letter to shareholders from the Company’s President and CEO, Gene Mack:

To our valued Shareholders,

As we progress through 2026 and look ahead to delivering continued significant progress, I want to thank you for your steadfast support of Gain Therapeutics. The year has been one of meaningful scientific progress as we achieved critical inflection points related to

Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update

Thu, 16 Jul 2026 07:00:00 -0400

To our valued Shareholders,

H.C. Wainwright Reiterates Buy Rating on Gain Therapeutics (GANX)

Wed, 01 Jul 2026 07:05:39 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $8.00 price target on Gain Therapeutics (NASDAQ: GANX).

The analyst commented: "This week, Gain Therapeutics reported that the FDA has authorized the company’s Investigational New Drug (IND) application for its lead candidate GT-02287. The FDA’s decision will allow the start of Gain’s Phase 2 clinical assessment of GT-02287 in Parkinson’s disease (PD) with or without a GBA1 mutation in the U.S. Both the Phase 1a and Phase 1b studies of GT-02287 were conducted in Australia. The sites in Australia are expected to also participate in the Phase 2 study along with

Form 8-K Gain Therapeutics, Inc. For: Jun 29

Mon, 29 Jun 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260629/26706749.html

Form 8-K Gain Therapeutics, Inc. For: Jun 29

Mon, 29 Jun 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260629/26706749.html

FDA clears Gain Therapeutics IND for GT-02287 Parkinson's Phase 2

Mon, 29 Jun 2026 16:05:13 -0400

Gain Therapeutics, Inc. (Nasdaq: GANX) announced that the U.S. Food and Drug Administration has cleared the company's Investigational New Drug application for GT-02287, allowing the company to initiate a Phase 2 clinical trial for Parkinson's disease in the United States.

The company expects to begin the Phase 2a study in the third quarter of 2026. The trial will enroll participants with early Parkinson's disease, with or without a GBA1 mutation, across sites in the United States, Australia, and Europe.

Phase 1a and Phase 1b studies of GT-02287 were conducted in Australia. In the ongoing Phase 1b extension study, all 16 participants remained

Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease

Mon, 29 Jun 2026 16:05:00 -0400

IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26

FDA’s decision follows positive Phase 1 results for GT-02287 in both healthy volunteers and people with Parkinson’s disease demonstrating both biomarker and clinical evidence of activity with favorable safety and tolerability

GT-02287 is the first allosteric modulator developed from Gain’s Magellan™ AI drug discovery platform to receive IND clearance

BETHESDA, Md., June 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the

Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease

Mon, 29 Jun 2026 16:05:00 -0400

IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26

GT-02287 is the first allosteric modulator developed from Gain’s Magellan™ AI drug discovery platform to receive IND clearance

BETHESDA, Md., June 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the

Form 8-K Gain Therapeutics, Inc. For: Jun 24

Thu, 25 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260625/26693272.html

Form 8-K Gain Therapeutics, Inc. For: Jun 24

Thu, 25 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260625/26693272.html